INTRODUCTION
============

The current standard of care for HIV-infected individuals includes routine monitoring of plasma virus load (VL) and genotypic testing for antiretroviral (ARV) drug resistance. In resource-rich as well as resource-limited public health settings, there is increasing demand for lower-cost and more feasible community-level virologic testing strategies for clinical monitoring and management of combination ARV therapy. The use of analyte alternatives to blood, particularly those that are easier to collect, have the potential to meet these demands.

Both HIV and anti-HIV antibodies can be detected in saliva \[[@R1]\], providing an alternative to blood to detect HIV antibodies to diagnose HIV infection \[[@R2]\]. Saliva HIV antibody tests with specialized devices for proper saliva specimen collection are currently licensed by the U.S. Food and Drug Administration (FDA) \[[@R3]\]. These tests are used in resource-limited settings as well as domestic public health clinics where rapid testing and ease of use are preferred \[[@R4]\]. The Centers for Disease Control (CDC) has included rapid HIV testing as part of its policy recommendations for HIV prevention programs \[[@R5]\]. The CDC has also recently promoted provider-initiated testing with reduced consent and counseling barriers, in order to increase accessibility to HIV testing and decrease the continued transmission of HIV \[[@R5],[@R6]\].

In voluntary counseling and testing centers, there is a growing interest in detecting acute infection among high-risk individuals. During acute infection, there is a brief period where high levels of HIV replication occur before the development of anti-HIV antibodies. Because VL levels are often greater than 100,000 copies/ml, methods to identify acutely-infected individuals include pooled screening of antibody negative plasma samples, which has substantially mitigated testing costs \[[@R7]\]. However, minimally invasive and lower cost sample collection methods have additional potential for increasing community-level identification of acute infection.

VL and drug resistance testing using saliva can help meet the increasing demands to identify acute seroconverters, identify transmitted drug resistance in public health screening for acute infection, and scale up community-based treatment monitoring. Although saliva has been successfully used for antibody testing and for field diagnosis of HIV infection, the feasibility of nucleic acid testing to both detect acute infection and to monitor individuals receiving ARV treatment has not been thoroughly examined. We investigated the feasibility of using saliva to detect and quantify HIV-1 RNA and to genotype HIV-1.

METHODS AND MATERIALS
=====================

Study Population
----------------

Sixty-nine HIV infected individuals were enrolled in this study under informed consent: 40 recruited from the San Francisco City Clinic (approved by the UCSF Committee for Human Research) and 29 from the Peninsula AIDS Research Consortium clinic at the San Mateo County AIDS Program (approved by the Mills-Peninsula/San Mateo Clinical Research Committee IRB). These were patients attending clinic for HIV care or sexually transmitted disease services. Among 40 patients at the San Francisco City Clinic, a questionnaire was administered for inclusion and exclusion purposes. Questions included presence of oral ulcers or sores, current bleeding in mouth, and whether there was eating, drinking, brushing teeth, flossing or smoking in the past hour prior to saliva collections. A yes answer to any of the questions excluded the individual from participating in the study.

Sample Collection
-----------------

Patients provided 5-10 ml of saliva by spitting into a sterile cup. Dried blood spots (DBS) were prepared from finger sticks onto Whatman 903 filter paper (approximately 50ul per DBS) and dried for several hours at room temperature prior to packaging and transporting to the processing lab. Saliva was frozen in the clinic and transported to the testing lab on dry ice. Both DBS and saliva were stored at -70c for up to two weeks prior to testing.

Sample Processing
-----------------

### RNA Extraction from Saliva and DBS

HIV-1 RNA plasma VLs were obtained from concurrently drawn clinical tests (Roche AMPLICOR HIV-1 Monitor assay, version 1.5), when available, or performed in house from DBS. Sixty-four virus loads were obtained from plasma while 5 were obtained from DBS. Saliva was homogenized (500uL) and centrifuged at 800g for 10 min to pellet debris, and the resulting supernatant was ultra centrifuged at 23,885 x g for 30 min to pellet virus to match the identical ultracentrifugation performed to pellet virus in corresponding patient plasma samples. The pellet was resuspended in 9mL of Nuclisens lysis buffer. For DBS, spots were placed directly into 9mL of Nuclisens lysis buffer and agitated for 2 hours at room temperature. The Roche Amplicor internal quantification standard (QS) was added to each saliva or DBS sample dissolved in lysis buffer, and RNA extraction completed according to the Nuclisens protocol (Biomerieux, Durham NC, USA). From this point, HIV VL was quantified using the ultrasensitive Roche AMPLICOR HIV-1 Monitor assay, version 1.5 (Roche Molecular Diagnostics, Branchberg NJ, USA), according to the manufacturer's instructions. DBS VL values were adjusted to account for sample volume input (50ul DBS). All VL values were normalized to 1 ml of fluid and expressed as RNA copies per ml. The lower limit of quantification was defined as 50 RNA copies/ml.

### Genotyping and Sequence Analysis

Genotyping was performed on samples with a VL greater than 200 copies/ml as previously described \[[@R8]\] when sufficient sample was available. Drug resistance mutations were identified using the Stanford HIV Drug Resistance Database (<http://HIVDB.stanford.edu>). Sequences were aligned with ClustalW \[[@R9]\] and a best-fit nucleotide substitution model was estimated using the program Modeltest \[[@R10]\] and manual examination in PAUP \[[@R11]\]. A maximum likelihood (ML) phylogenetic tree (Fig.**[1](#F1){ref-type="fig"}**) was constructed under this model with the program PhyML. Genetic distances between paired saliva and plasma sequences were estimated from this tree.

RESULTS
=======

Validation of VL Determination from DBS and Saliva
--------------------------------------------------

Virus spiking experiments were performed to determine the best method for isolating RNA from saliva. High VL HIV-1 plasma of known copy was diluted to 50,000 copies/mL, 10,000 copies/mL and 2,000 copies/mL in normal human plasma and saliva. HIV-1 RNA was successfully recovered from saliva and plasma using Ultrasensitive Roche AMPLICOR HIV-1 Monitor assay Extraction or the Ultrasensitive Nuclisens Extraction Kit. However, the Roche QS was not efficiently recovered from saliva using the Amplicor extraction method \[[@R12]\] (data not shown), resulting in inaccurate VL measurements. The Ultrasensitive Nuclisens Kit was able to recover both HIV-1 and QS from spiked plasma and saliva as well as negative control samples with equal efficiency, and this method was used to extract RNA for both VL and genotype determinations.

In five cases, the timing and location of specimen acquisition did not include an appropriate plasma sample for VL determination. In these cases, DBS were assayed to determine plasma VL. To validate the use of DBS to measure VL, matched pairs of plasma and DBS were collected from 32 subjects, and VL (median DBS VL=5419, range=49-3,301,925copies/mL) determined on each specimen as described in Materials and Methods. Results (Fig. **[2a](#F2a){ref-type="fig"}**) indicate a significant correlation between plasma-derived and DBS derived VL values (p\<0.0001). There was a median 0.18 log~10~RNA copies/ml difference between plasma and DBS VL values. Based on the strong correlation and small differences between plasma and DBS VL, the five subjects with DBS-derived VL measurements were included in the study.

Saliva Virus Load
-----------------

Overall, HIV-1 RNA was detected in 47 of 69 (68%) plasma and 39 of 69 (56%) saliva specimens. Of the 47 subjects with plasma viremia (median 22,514 copies/ml, range 68 to 1,244,229 copies/ml); 36 patients (77%) had measurable HIV RNA in saliva (median 75 copies/ml, range 52 to 141,621 copies/ml). There was a significant correlation between plasma and saliva VL in these subjects (Fig. **[2b](#F2b){ref-type="fig"}**), p\<.0001). Patients with detectable saliva VL had a median plasma VL of 33,530 copies/ml, range 0 to 1,244,229 copies/ml. Patients without detectable saliva had a median plasma VL of 0 copies/ml, and range 0 to 109,000 copies/ml Plasma VLs were higher than saliva VL levels by an average 0.9 log~10~ RNA copies/ml. Two subjects exhibited a higher VL in saliva than in plasma, while three subjects had detectable HIV-1 RNA in saliva but had undetectable plasma VL.

Sequence Conservation and Drug Resistance Between Plasma and Saliva
-------------------------------------------------------------------

To our knowledge, there is no previous literature reporting the sequencing of the *gag-pol* gene of HIV-1 from saliva specimens. A *gag-pol* fragment of nearly 1,000 base-pairs was sequenced from both plasma and saliva in 20 subjects. A phylogenetic tree showed that saliva and plasma sequences within individuals were 1) closely related (average genetic distance 0.0043 nucleotide substitutions/site; range 0.0011-0.0196); 2) highly concordant (average genotypic concordance \>99% at both the nucleotide and AA level); and 3) segregated by subject. Thirteen subjects had genotypic resistance mutations in either plasma, saliva, or both (Table **[1](#T1){ref-type="table"}**). In the protease (PR) gene, nine patients had minor resistance mutations (L10I, A71AV and A71V) with no major resistance mutations. Discordance in the presence of PR mutations between plasma and saliva was found in five subjects; in each case a minor PR mutation was found in the plasma that was not present in saliva. In the reverse transcriptase (RT) region, six patients were found to harbor resistance mutations (D67N, K103N, V108I, V118I, E138A, G190A and the revertant mutation T215S). Differences in RT resistance mutations were seen between plasma and saliva genotypes in four of six subjects; in two subjects mutations were identified in saliva but not plasma, and in two subjects mutations were found in plasma but not in saliva. In the PR gene 7/19 sequences demonstrated at least one difference between saliva and plasma in polymorphic residues associated with protease inhibitor resistance (secondary or minor mutations), while 4/19 RT sequences differed at major drug resistance codons.

DISCUSSION
==========

Previous studies have shown that non-plasma samples, including oral transudate, urine, and DBS, are appropriate analytes for the detection of antibodies to HIV to diagnose HIV infection \[[@R2]\]. As a candidate diagnostic analyte, saliva can be easily obtained at lower cost and without the discomfort, invasiveness, and subsequent risks associated with needle use and disposal in conventional phlebotomy. Similarly, DBS provide an alternative means of blood collection for VL testing \[[@R13]\]. We have found that among public health clinic patients, HIV-1 RNA could be successfully isolated, extracted, reverse transcribed and amplified from a relatively small volume of saliva (500ul). Comparison of viral RNA detection and quantification from saliva and plasma demonstrated that most subjects (83%) with more than 1,000 RNA copies/ml in plasma had detectable viral RNA in their oral secretions (Table **[2a](#T2a){ref-type="table"}**).

Comparison of DBS and plasma for the detection and quantification of HIV-1 RNA showed good correlation (Fig.**[2a](#F2a){ref-type="fig"}**). This is consistent with a growing literature in which dried blood spots have been evaluated in comparison to plasma \[[@R14]\]. As expected from previous studies \[[@R15],[@R16]\], VL in saliva contained less HIV-1 RNA compared to plasma, however most viremic patients in our study had detectable saliva RNA. Overall, the sensitivity of saliva VL was found to be 77% compared to plasma (Table **[2b](#T2b){ref-type="table"}**). Sensitivity could be low for technical or biological reasons. There might not be any HIV present in the saliva compartment for some patients due to no localized replication. While this sensitivity may be insufficient to monitor patients on suppressive ARV, the high proportion of saliva RNA-positivity when plasma VL is higher (95% at plasma VL \> 33,500 copies/ml) may make saliva a suitable analyte for evaluating untreated or acutely-infected individuals.

Although HIV-1 is transmitted through blood, semen, breast milk, and cervical secretions, the evidence for transmissible virus in saliva is less convincing \[[@R17]\]. In the past, researchers have found that VL from non blood sources can be 1 to 2 log values lower than VL from corresponding plasma samples. The relatively low level of virus in saliva (median saliva VL= 75copies/mL) may be one explanation for the apparent infrequency of transmission of virus from saliva \[[@R18],[@R19]\]. However, transmission rates are higher in other non blood analytes than in saliva regardless of lower VLs in those compartments. There is proposed evidence to suggest existence of anti viral activity in the oral environment preventing HIV-1 transmission \[[@R19]\]. We were surprised to identify three individuals who had detectable saliva VL while having a plasma VL of \< 50 copies/ml. In addition we found two individuals with saliva HIV-1 RNA levels (\> 20,000 copies/ml) that were 2 to 5-fold greater than their respective plasma levels. It is possible that undetected inflammatory responses in the oral cavity may have increased the VL in the patients' respective saliva. Although multiple studies of HIV-1 RNA in virus particles from non-blood fluids have shown evidence for compartmentalized viral replication \[[@R12]\], in our study, it is unclear if independent replication is occurring in different biological compartments. In the present analysis, differences in the detection and quantification of viral RNA in a small number of subjects suggest that the oral cavity may support compartmental replication and shedding in HIV-infected individuals and these rates of replication may be different for different patients. However, further studies need to be performed to further evaluate this as inflammatory conditions of the mouth were not closely examined.

Several viral characteristics may be inferred from sequence analysis of HIV RNA including subtype, diversity \[[@R20]\], drug resistance \[[@R21]\] and envelope tropism \[[@R22]\]. Our phylogenetic comparisons of *gag-pol* gene sequences obtained from DBS, plasma and saliva showed considerable sequence homology and provided assurance that sample-mix-up or contamination did not occur. These findings are in agreement with previous studies where sequencing of the envelope gene in saliva and plasma was concordant \[[@R22]\]. However, while comparison of plasma and saliva HIV-1 *pol*-genes demonstrated only modest overall differences (\<1%) in nucleic and amino acid sequences from each compartment, examination of specific codons suggest potentially important differences between saliva and plasma virus. In 8/20 patients, drug-associated resistance mutations in the PR and/or RT gene were found in only one compartment. These differences were primarily found at minor mutation sites in our population of primarily untreated patients, except for one treated patient where a K103N mutation was found in plasma-associated virus but not in saliva. While it is possible that sampling bias may have affected our ability to detect mutations in different compartments, all of the samples genotyped met similar viral load criteria (\>200 copies/ml) to be included in the analysis. Our findings of different genotype profiles in plasma *vs* saliva suggest variations in selective pressure between these two compartments. Further analysis of resistance mutations between saliva and plasma in highly ARV experienced patients is needed to further evaluate this hypothesis.

In summary, saliva may be a useful analyte for detection of HIV-1 when HIV-1 RNA levels are high, such as in acute HIV infection. In monitoring responses to ARV therapy, saliva VL measures have reduced sensitivity and may not accurately reflect VL in plasma, but nevertheless could identify high-level viremia during treatment failure. The use of HIV-1 sequences to monitor drug resistance may be possible, although additional analysis of compartmental differences is needed. Further studies on compartmental differences in HIV viremia and drug resistance can help optimize saliva testing as an alternative analyte for monitoring patients in clinical settings.

California HIV Research Program (CHRP) grant: CH05-SMCH-612.

Poster presented at International AIDS Conference, Mexico City, Mexico, August 2008.

![Maximum likelihood phylogenetic tree of HIV-1 protease and reverse transcriptase genes comparing blood and saliva samples. (942 nucleotides total; PR codons 22-99 and RT codons 1-238).](TOVJ-4-88_F1){#F1}

![Correlation of plasma HIV-1 RNA with DBS HIV-1 RNA.](TOVJ-4-88_F2a){#F2a}

![Correlation of plasma HIV-1 RNA with saliva HIV-1 RNA.](TOVJ-4-88_F2b){#F2b}

###### 

Protease and Reverse Transcriptase Mutations

          [Protease]{.ul}   [Reverse Transcriptase]{.ul}                                                    
  ------- ----------------- ------------------------------ ----------- ----------------- ------------------ -------------------------
  101     no                no                             none        none              none               none
  103     no                no                             none        **L10I**          **D67N**           none
  104     no                no                             **A71AV**   **A71AV, L10I**   none               none
  105     no                no                             none        none              none               none
  108     no                no                             none        **L10I**          none               none
  110     no                yes                            none        **L10I**          none               none
  114     no                no                             none        **L10I**          none               none
  128     no                no                             none        none              none               none
  129     no                no                             none        none              **K103N**          **K103N**
  130     no                yes                            none        none              none               **K103N**
  131     no                no                             none        none              none               none
  132     no                no                             **L10I**    **L10I**          none               none
  137     no                no                             **L10I**    **L10I**          none               none
  138     no                no                             none        **L10I**          none               none
  141     no                no                             none        none              none               none
  10047   unavailable       unavailable                    none        none              none               none
  30007   unavailable       n/a                            none        **A71V**          **V118I**          none
  123     yes               yes                            none        none              none               none
  126     yes               yes                            none        none              **T215S, G190A**   **T215S, G190A, E138A**
  10028   yes               n/a                            none        none              **V108I**          **V108I**

###### 

Presence of HIV-1 RNA in Saliva at Different Plasma RNA levels (n=81)

  Plasma Virus Load      \# Subjects   No. Subjects with Detectable Saliva RNA
  ---------------------- ------------- -----------------------------------------
  100,000-1,200,000      11            10 (91%)
  10,000-99,999          20            17 (85%)
  1,000-9,999            10            7 (70%)
  50-999                 6             2 (33%)
  \<50                   22            3 (14%)
  HIV Negative Control   12            0 (0%)

###### 

Sensitivity of Saliva HIV-1 Virus Load Detection (n=69).

                    Saliva (95%CI)
  ----------------- ----------------
  **Sensitivity**   .77(.62-.87)
